Preclinical Development
Stefan Linehan, MS
VP of Operations and Development
TissueVision Inc.
Newton, Massachusetts
Description: When the FDA requests more information from pre-clinical models to assess safety related issues identified in clinical studies, what modality do you turn to? Naturally, ex vivo imaging provides high resolution content to answer such questions, but conventionally lacks translatability to the clinic. TissueVision’s novel Serial Two-Photon Plus platform provides a solution to span the gap between ex vivo and in vivo translational data evaluation. The resulting ex vivo 3D models can be integrated back to the pre-clinical in vivo 3D data, creating a translational bridge to the clinical in vivo imaging.